BRPI0912428A2 - formulação farmacêutica sólida de liberação retardada - Google Patents

formulação farmacêutica sólida de liberação retardada

Info

Publication number
BRPI0912428A2
BRPI0912428A2 BRPI0912428A BRPI0912428A BRPI0912428A2 BR PI0912428 A2 BRPI0912428 A2 BR PI0912428A2 BR PI0912428 A BRPI0912428 A BR PI0912428A BR PI0912428 A BRPI0912428 A BR PI0912428A BR PI0912428 A2 BRPI0912428 A2 BR PI0912428A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
delayed release
release pharmaceutical
solid delayed
solid
Prior art date
Application number
BRPI0912428A
Other languages
English (en)
Inventor
Axel Schmidt
Gertraut Altreuther
Martina Rehagen
Michael Träubel
Thomas Bach
Venkata-Rangarao Kanikanti
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40846135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0912428(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of BRPI0912428A2 publication Critical patent/BRPI0912428A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0912428A 2008-05-07 2009-04-23 formulação farmacêutica sólida de liberação retardada BRPI0912428A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008022520A DE102008022520A1 (de) 2008-05-07 2008-05-07 Feste Arzneimittelformulierung mit verzögerter Freisetzung
PCT/EP2009/002951 WO2009135593A2 (de) 2008-05-07 2009-04-23 Feste arzneimittelformulierung mit verzögerter freisetzung

Publications (1)

Publication Number Publication Date
BRPI0912428A2 true BRPI0912428A2 (pt) 2016-02-16

Family

ID=40846135

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0912428A BRPI0912428A2 (pt) 2008-05-07 2009-04-23 formulação farmacêutica sólida de liberação retardada

Country Status (29)

Country Link
US (2) US20110046072A1 (pt)
EP (1) EP2285359B1 (pt)
JP (1) JP5539966B2 (pt)
KR (1) KR101663501B1 (pt)
CN (1) CN102215824B (pt)
AR (1) AR071620A1 (pt)
AU (1) AU2009243759B2 (pt)
BR (1) BRPI0912428A2 (pt)
CA (1) CA2723553C (pt)
CL (1) CL2009001016A1 (pt)
CO (1) CO6311067A2 (pt)
DE (1) DE102008022520A1 (pt)
DK (1) DK2285359T3 (pt)
DO (1) DOP2010000331A (pt)
EC (1) ECSP10010588A (pt)
ES (1) ES2393169T3 (pt)
IL (1) IL208486A0 (pt)
MX (1) MX2010012025A (pt)
MY (1) MY159492A (pt)
NI (1) NI201000189A (pt)
NZ (1) NZ589017A (pt)
PE (1) PE20091949A1 (pt)
PL (1) PL2285359T3 (pt)
PT (1) PT2285359E (pt)
RU (1) RU2548733C9 (pt)
TW (1) TWI441644B (pt)
UA (1) UA103025C2 (pt)
UY (1) UY31788A (pt)
WO (1) WO2009135593A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102258769B1 (ko) * 2011-10-14 2021-06-01 지엘팜텍주식회사 장용소화효소제 및 그 제조방법
MY175307A (en) * 2011-12-21 2020-06-18 Bayer Ip Gmbh Preparations comprising amorphous emodepside
KR101400791B1 (ko) * 2012-10-04 2014-05-29 주식회사대성미생물연구소 동물용 복합 기능성 항생제 조성물
MY175703A (en) * 2012-12-19 2020-07-06 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
WO2016141065A1 (en) * 2015-03-03 2016-09-09 Kindred Biosciences, Inc. Compositions and methods for treatment and prevention of pyrexia in horses
SG11201708008TA (en) 2015-04-02 2017-10-30 Merial Inc Anthelmintic combinations and methods of use thereof
CN114891070A (zh) 2015-05-20 2022-08-12 勃林格殷格翰动物保健美国公司 驱虫缩酚酸肽化合物
KR20220003663A (ko) 2015-12-28 2022-01-10 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충성 뎁시펩티드 화합물
WO2017213208A1 (ja) * 2016-06-09 2017-12-14 Ｄｓファーマアニマルヘルス株式会社 動物用徐放性製剤組成物
MX2019005628A (es) 2016-11-16 2019-12-18 Boehringer Ingelheim Animal Health Usa Inc Compuestos depsipeptidos antihelminticos.
CN108888598A (zh) * 2018-08-01 2018-11-27 江西成必信生物科技有限公司 口服易吸收的布他磷及其制备方法
JP7268340B2 (ja) * 2018-12-06 2023-05-08 コニカミノルタ株式会社 ３ｄプリンター成形用樹脂組成物及びそれを用いた成形体とその製造方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2362539C2 (de) 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3472678D1 (de) 1983-07-18 1988-08-18 Beecham Group Plc Benzazepine and benzoxazepine derivatives
NO176766C (no) 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
NL9000238A (nl) * 1990-01-31 1991-08-16 Aesculaap Bv Veterinair fenytoinepreparaat.
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
WO1993019053A1 (en) * 1992-03-17 1993-09-30 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide derivative, production thereof and use thereof
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4317458A1 (de) * 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
JP3140465B2 (ja) * 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
AU695021B2 (en) 1993-02-19 1998-08-06 Meiji Seika Kaisha Ltd. PF1022 derivative cyclic depsipeptide
DE4317457A1 (de) * 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317432A1 (de) 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
US5646244A (en) * 1993-09-06 1997-07-08 Fujisawa Pharmaceutical Co., Ltd. Cyclodepsipeptide compound
DE4401389A1 (de) * 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) * 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
NZ283160A (en) * 1994-05-06 1998-07-28 Pfizer Azithromycin in a controlled release dosage form for treating microbiol infections
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
CN1162409C (zh) 1995-06-30 2004-08-18 藤泽药品工业株式会社 缩肽衍生物、其新型中间体以及中间体的制造方法
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
IL123776A (en) * 1995-09-22 2002-09-12 Bayer Ag History of Cyclodepsipeptide 1022 PF
DE19545639A1 (de) * 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
IT1303693B1 (it) * 1998-11-03 2001-02-23 Formenti Farmaceutici Spa Composizioni a rilascio controllato di metamizolo.
DE19920415A1 (de) * 1999-05-04 2000-11-09 Hexal Ag Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
DE10031044A1 (de) * 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
IL159715A0 (en) * 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
WO2004093915A1 (en) * 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
US7396819B2 (en) * 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE04801160T1 (de) * 2003-12-01 2007-08-09 Lifecycle Pharma A/S Pharmazeutische zusammensetzungen mit lercanidipin
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PL2012763T3 (pl) * 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
EP2050438B1 (en) * 2006-07-26 2016-10-19 Asahi Kasei Kabushiki Kaisha Spherical crude granule and method for production thereof
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
DE102007012644A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Stabilisierung von Vitamin B12

Also Published As

Publication number Publication date
TW201010714A (en) 2010-03-16
DOP2010000331A (es) 2010-12-15
DK2285359T3 (da) 2012-11-26
CN102215824A (zh) 2011-10-12
KR20110015592A (ko) 2011-02-16
CO6311067A2 (es) 2011-08-22
RU2548733C2 (ru) 2015-04-20
CN102215824B (zh) 2015-06-03
HK1162936A1 (en) 2012-09-07
AU2009243759A1 (en) 2009-11-12
PT2285359E (pt) 2012-11-26
NI201000189A (es) 2011-08-10
RU2010149561A (ru) 2012-06-20
MX2010012025A (es) 2010-12-07
CA2723553C (en) 2016-08-30
UA103025C2 (ru) 2013-09-10
EP2285359A2 (de) 2011-02-23
DE102008022520A1 (de) 2009-11-12
UY31788A (es) 2009-12-14
PL2285359T3 (pl) 2013-01-31
JP5539966B2 (ja) 2014-07-02
JP2011519878A (ja) 2011-07-14
ECSP10010588A (es) 2010-12-30
WO2009135593A2 (de) 2009-11-12
EP2285359B1 (de) 2012-09-05
US20110046072A1 (en) 2011-02-24
PE20091949A1 (es) 2009-12-25
WO2009135593A3 (de) 2011-01-06
RU2548733C9 (ru) 2015-12-20
NZ589017A (en) 2012-11-30
KR101663501B1 (ko) 2016-10-07
US20150150985A1 (en) 2015-06-04
AR071620A1 (es) 2010-06-30
ES2393169T3 (es) 2012-12-19
IL208486A0 (en) 2010-12-30
TWI441644B (zh) 2014-06-21
CA2723553A1 (en) 2009-11-12
CL2009001016A1 (es) 2010-08-13
MY159492A (en) 2017-01-13
AU2009243759B2 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
DK2345410T3 (da) Farmaceutisk sammensætning til modificeret frigivelse
BRPI0912428A2 (pt) formulação farmacêutica sólida de liberação retardada
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0908596A2 (pt) formulação e composição farmacêutica de liberação prolongada
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BR112012011733A2 (pt) formulações de comprimido de liberação imediata
BRPI0907884A2 (pt) Partícula de liberação
BRPI0909220A2 (pt) Partícula de liberação
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI0920521A2 (pt) combinação farmacêutica
BRPI0916612A2 (pt) partícula de liberação
EP2451274A4 (en) Pharmaceutical compositions
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
SMT201400069B (it) Formulazione farmaceutica
IL207378A0 (en) Pharmaceutical solid state forms
BRPI0908114A2 (pt) tabuleta oral de liberação controlada
BRPI0921654A2 (pt) formulação farmacêutica
PL2379086T3 (pl) Preparat farmeceutyczny
DK2391351T3 (da) Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
DK2285413T3 (da) Farmaceutisk sammensætning
BRPI0906754A2 (pt) Formulário de dosage prolongado da libertação de paliperidone
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0922423A2 (pt) dispositivo de liberação de fármaco
BRPI0811732A2 (pt) Formulação de liberação prolongada de nevirapina

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.